Amylyx Pharmaceuticals, Inc. (AMLX) stock
Close on Nov 13, 2026Market cap $3.38BP/E –Yield –
Earnings
Amylyx Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Amylyx Pharmaceuticals's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 2, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026before the open | – | – | -$0.38 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026before the open | – | – | -$0.39 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026before the open | – | – | -$0.37 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 3, 2026before the open | – | – | -$0.30 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025before the open | – | – | -$0.37 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025before the open | – | – | -$0.46 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025before the open | – | – | -$0.42 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 4, 2025before the open | -$665.00K | -100.6% | -$0.55 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 7, 2024before the open | – | – | -$1.07 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024before the open | -$1.00M | -101.0% | -$1.07 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 9, 2024before the open | $88.60M | +24.1% | -$1.75 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 22, 2024before the open | $108.40M | +395.0% | $0.07 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 9, 2023before the open | $102.70M | +34133.3% | $0.30 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 10, 2023after the close | $98.20M | – | $0.31 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 11, 2023after the close | $71.40M | – | $0.02 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 13, 2023after the close | $21.90M | – | -$0.65 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 10, 2022after the close | $300.00K | – | -$0.92 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 11, 2022after the close | – | – | -$0.93 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 12, 2022after the close | – | – | -$0.93 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 31, 2022after the close | – | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Amylyx Pharmaceuticals has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Amylyx Pharmaceuticals puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Amylyx Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Update
- Results
- Results
- Update
- Results
- Update
- Results
- Results
- Results
- Results
- Results
- Results
- Results
See a number that looks wrong?